David J Inwards
Overview
Explore the profile of David J Inwards including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
152
Citations
3658
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Velazquez A, Inwards D, Ansell S, Micallef I, Johnston P, Hogan W, et al.
J Cancer Ther
. 2025 Mar;
4(8):1298-1305.
PMID: 40051827
Day 100 prognostic factors post-autologous peripheral blood hematopoietic stem cell transplantation (APBHSCT) to predict clinical outcomes in diffuse large B-cell lymphoma (DLBCL) patients have not been studied. Thus, we retrospectively...
2.
Tun A, Wang Y, Maliske S, Micallef I, Inwards D, Habermann T, et al.
Transplant Cell Ther
. 2024 Jul;
30(10):1001.e1-1001.e12.
PMID: 38996973
The standard of care (SOC) for fit patients with relapsed diffuse large B-cell lymphoma (DLBCL) ≥12 months after completing frontline therapy is salvage chemotherapy (ST) followed by autologous stem cell...
3.
Smith M, Jegede O, Martin P, Till B, Parekh S, Yang D, et al.
Blood
. 2024 May;
144(10):1083-1092.
PMID: 38820500
Although initial therapy of mantle cell lymphoma (MCL) is not standardized, bendamustine plus rituximab (BR) is commonly used in older patients. Rituximab (R) maintenance after induction is often used. Thus,...
4.
Tun A, Wang Y, Maliske S, Micallef I, Inwards D, Habermann T, et al.
Haematologica
. 2024 Jan;
109(7):2186-2195.
PMID: 38235513
Chimeric antigen receptor T-cell therapy is the new standard of care in fit patients with refractory or early relapsed diffuse large B-cell lymphoma (DLBCL). However, there may still be a...
5.
Burlile J, Frechette K, Breen W, Hwang S, Higgins A, Nedved A, et al.
Blood Adv
. 2024 Jan;
8(5):1250-1257.
PMID: 38206755
Immune checkpoint inhibitors (ICIs) have demonstrated remarkable response rates in relapsed or refractory Hodgkin lymphoma (HL). Still, most patients eventually progress. Patterns of progression after ICIs are not well described...
6.
Kasten M, Lahr B, Parisapogu A, Yetmar Z, OHoro J, Orenstein R, et al.
Sci Rep
. 2023 Dec;
13(1):21249.
PMID: 38040756
The role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) convalescent plasma in the treatment of Coronavirus Disease 2019 (COVID-19) in immunosuppressed individuals remains controversial. We describe the course of...
7.
Bock A, Gile J, Larson M, Poonsombudlert K, Tawfiq R, Maliske S, et al.
Blood Cancer J
. 2023 Nov;
13(1):169.
PMID: 37957158
Over the last two decades, the frontline therapy for mantle cell lymphoma (MCL) has evolved. However, the impact of subsequent lines of therapy on survival outcomes has not been well...
8.
Gerson J, Handorf E, Villa D, Gerrie A, Chapani P, Li S, et al.
Blood Adv
. 2023 Oct;
7(24):7393-7401.
PMID: 37874912
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma; data indicate that blastoid and pleomorphic variants have a poor prognosis. We report characteristics and outcomes of patients with blastoid/pleomorphic variants...
9.
Rezazadeh A, Szabo A, Khurana A, Inwards D, Lunning M, Bartlett N, et al.
Haematologica
. 2023 Oct;
109(5):1439-1444.
PMID: 37855051
Primary bone diffuse large B-cell lymphoma is a rare variant of extranodal non-Hodgkin lymphoma historically treated with induction chemotherapy followed by consolidative radiation therapy (RT). It remains unknown whether RT...
10.
Tun A, Wang Y, Matin A, Inwards D, Habermann T, Micallef I, et al.
Hemasphere
. 2023 Apr;
7(4):e869.
PMID: 37034004
Immune checkpoint inhibitors (ICIs) and brentuximab vedotin (BV) are novel agents for classic Hodgkin lymphoma, including relapse after autologous stem cell transplant (ASCT). However, their impact on survival post-ASCT relapse,...